GUD:CA:TSX-Knight Therapeutics Inc. (CAD)

EQUITY | Drug Manufacturers - Specialty & Generic | Toronto Stock Exchange

Last Closing

CAD 5.65

Change

0.00 (0.00)%

Market Cap

CAD 1.31B

Volume

0.04M

Analyst Target

CAD 8.74
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Knight Therapeutics Inc is a specialty pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-16 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
BHC:CA Bausch Health Companies Inc

+0.27 (+2.99%)

CAD 3.45B
TLRY:CA Tilray Inc

-0.03 (-2.34%)

CAD 1.52B
CURA:CA Curaleaf Holdings Inc.

-0.01 (-0.50%)

CAD 1.36B
CRON:CA Cronos Group Inc

+0.03 (+1.09%)

CAD 1.06B
DHT-UN:CA DRI Healthcare Trust

-0.02 (-0.17%)

CAD 0.75B
AOV:CA Amotiv Limited

N/A

CAD 0.58B
DHT-U:CA DRI Healthcare Trust

N/A

CAD 0.54B
WEED:CA Canopy Growth Corp

-0.06 (-2.48%)

CAD 0.46B
ACB:CA Aurora Cannabis Inc

-0.33 (-3.85%)

CAD 0.36B
CPH:CA Cipher Pharmaceuticals Inc

-0.18 (-1.41%)

CAD 0.33B

ETFs Containing GUD:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (Toronto Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.81% 70% C- 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.81% 70% C- 80% B-
Trailing 12 Months  
Capital Gain 1.25% 71% C- 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.25% 71% C- 16% F
Trailing 5 Years  
Capital Gain -24.26% 86% B+ 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.26% 86% B+ 13% F
Average Annual (5 Year Horizon)  
Capital Gain -1.77% 55% F 19% F
Dividend Return -1.77% 55% F 12% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 14.30% 100% F 58% F
Risk Adjusted Return -12.39% 45% F 14% F
Market Capitalization 1.31B 74% C 61% D-

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (Toronto Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 74.10 53% 13%
Price/Book Ratio N/A N/A N/A
Price / Cash Flow Ratio N/A N/A N/A
Price/Free Cash Flow Ratio N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A
Return on Invested Capital 1.47% 74% 33%
Return on Assets N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector